Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis
Main Article Content
Keywords
clinical decision making, predictive markers, renal cell cancer, second-line therapy, targeted therapy
Abstract
Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a second-line therapy. Therefore, the choice at each subsequent treatment line remains an important issue. In this retrospective study, we sought to identify pretreatment clinical parameters that could predict the likelihood of a patient receiving a second-line therapy. One hundred and sixty-one mRCC patients who received targeted therapy were evaluated. Descriptive statistics, Kaplan–Meier overall survival (OS), Cox regression, and binary logistic regression models were used for data analysis. Second-line therapy was given to 105 patients (65%). Patients with grade 1 tumor received second-line therapy more frequently than those with grade 2/3 tumors (P = 0.03). Only tumor grade was significantly different between patients receiving, or not receiving, second-line treatment. Median OS was significantly superior in patients receiving second-line therapy (32 versus 14 months; P = 0.007; hazard ratio [HR], 1.75; P = 0.008), patients with grade 1 tumors (130 versus 29 months in G2/3 tumors; HR, 3.85; P = 0.009), and in patients without early tumor progression (41 versus 11 months; HR, 5.04; 95% confidence interval [CI], 3.06–8.31; P < 0.001). In binary logistic regression, we identified early progression to be significantly associated with a higher probability of not receiving a second-line therapy (HR, 2.50; 95% CI, 1.01–6.21; P = 0.048). This study hypothesizes that pretreatment grade and early progression are predictive parameters for the selection of patients for second-line therapy.
References
2. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Jan9;32(25):2765–72.
3. Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, et al. SWITCH: A randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol [Internet]. [cited 2015 Sep 1]; Available from: http://www.sciencedirect.com/science/article/pii/S030228381500319X.
4. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2002 Jan1;20(1):289–96. http://dx.doi.org/10.1200/JCO.2002.20.1.289.
5. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. Lancet Oncol. 2013 Feb;14(2):141–8. http://dx.doi.org/10.1016/S1470-2045(12)70559-4.
6. Ko JJ, Xie W, Kroeger N, Lee J-L, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: A population-based study. Lancet Oncol. 2015 Mar;16(3):293–300. http://dx.doi.org/10.1016/S1470-2045(14)71222-7.
7. Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, et al. Metastatic tumor burden does not predict overall survival following cytoreductive nephrectomy for renal cell carcinoma; a novel 3-dimensional volumetric analysis. Urology. 2017 Feb;100:139–44. http://dx.doi.org/10.1016/j.urology.2016.09.016.
8. Modi PK, Farber NJ, Singer EA. Precision oncology: Identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma. Transl Cancer Res. 2016 Jun;5(Suppl 1):S76–80.
9. Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, et al. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. Br J Cancer. 2016 Mar15;114(6):642–9. http://dx.doi.org/10.1038/bjc.2016.21.
10. Gu L, Ma X, Wang L, Li H, Chen L, Li X, et al. Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model. Oncotarget. 2016 Jul16; http://dx.doi.org/10.18632/oncotarget.10626.
11. Bianconi M, Faloppi L, Loretelli C, Zizzi A, Giampieri R, Bittoni A, et al. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget. 2016 Jun21;7(25):37599–607. http://dx.doi.org/10.18632/oncotarget.9229.
12. Alimohamed N, Lee J-L, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2014 Aug;12(4):e127–131. http://dx.doi.org/10.1016/j.clgc.2013.12.003.
13. Chrom P, Stec R, Semeniuk-Wojtas A, Bodnar L, Spencer NJ, Szczylik C. Fuhrman grade and neutrophil-to-lymphocyte ratio influence on survival in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Clin Genitourin Cancer. 2016 Oct;14(5):457–64. http://dx.doi.org/10.1016/j.clgc.2016.02.005.
14. Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, et al. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer. 2012 Oct9;107(8):1227–32. http://dx.doi.org/10.1038/bjc.2012.327.
15. Sacré A, Barthélémy P, Korenbaum C, Burgy M, Wolter P, Dumez H, et al. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Acta Oncol Stockh Swed. 2016;55(3):329–40. http://dx.doi.org/10.3109/0284186X.2015.1099731.
16. Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952–8. http://dx.doi.org/10.1016/j.eururo.2014.12.036.
17. Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Négrier S, et al; International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group. Clin Cancer Res Off J Am Assoc Cancer Res. 2011 Aug15;17(16):5443–50. http://dx.doi.org/10.1158/1078-0432.CCR-11-0553.
18. Escudier B, Albiges L, Sonpavde G. Optimal management of metastatic renal cell carcinoma: Current status. Drugs. 2013 Apr;73(5):427–38. http://dx.doi.org/10.1007/s40265-013-0043-1.
19. Powles T, Crusz SM. Sequencing systemic therapies in advanced RCC: Is there a best strategy? Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet. 2013.
20. Bourlon MT, Kessler ER. What next? Choosing second-line therapy in progressive renal cell carcinoma. Oncology (Williston Park). 2014 Sep;28(9):794–6.
21. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, et al; International mRCC Database Consortium. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol. 2013 Sep;8(3):203–9. http://dx.doi.org/10.1007/s11523-012-0252-7.
22. Park YH, Ku JH, Kwak C, Kim HH. Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy. Springerplus. 2014;3:243. http://dx.doi.org/10.1186/2193-1801-3-243.
23. Winer AG, Motzer RJ, Hakimi AA. Prognostic biomarkers for response to vascular endothelial growth factor-targeted therapy for renal cell carcinoma. Urol Clin North Am. 2016 Feb;43(1):95–104. http://dx.doi.org/10.1016/j.ucl.2015.08.009.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.